Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
2020; Elsevier BV; Volume: 396; Issue: 10245 Linguagem: Inglês
10.1016/s0140-6736(20)30734-0
ISSN1474-547X
AutoresMeletios Α. Dimopoulos, Hang Quach, María‐Victoria Mateos, Ola Landgren, Xavier Leleu, David S. Siegel, Katja Weisel, Hui Yang, Zandra Klippel, Anita Zahlten‐Kumeli, Saad Z. Usmani,
Tópico(s)Protein Degradation and Inhibitors
Referência(s)